2012
DOI: 10.1016/j.jval.2012.08.1670
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: OBJECTIVES: To evaluate the health care cost for the management of diabetes along with other co-morbidities condition before and after counseling. METHODS: A Prospective interventional study was conducted in the community setup of Warangal, India for a period of four months. Only the educated Diabetic patients with other comorbidities were enrolled in the study. The data collected were cost of medications, lab tests, consultation fee, transportation cost. The average total health care cost was calculated based… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The total annual direct cost per patient increased with the number of complications (Figure 1), primarily driven by inpatient and medication costs. The mean direct costs per patient associated with incident, acute macrovascular, microvascular, and metabolic complications ranged from €11,548 (acute coronary syndrome, France) [172] to €26,090 (incident cardiovascular disease [CVD], UK [173]) in EST markets and from €1,504 (ischemic heart disease, China [174]) to €8,786 (acute myocardial infarction, China [175]) in EMG markets. The mean direct costs per episode per patient associated with the management of chronic comorbidities ranged from €1,323 (retinopathy, Italy [176]) to €9,497 (established CVD, UK [173]) in EST markets and from €769 (microvascular disease, China [177]) to €4,865 (chronic kidney disease (CKD), China [178]) in EMG markets (Figure 2).…”
Section: Epidemiology: Complicationsmentioning
confidence: 99%
“…The total annual direct cost per patient increased with the number of complications (Figure 1), primarily driven by inpatient and medication costs. The mean direct costs per patient associated with incident, acute macrovascular, microvascular, and metabolic complications ranged from €11,548 (acute coronary syndrome, France) [172] to €26,090 (incident cardiovascular disease [CVD], UK [173]) in EST markets and from €1,504 (ischemic heart disease, China [174]) to €8,786 (acute myocardial infarction, China [175]) in EMG markets. The mean direct costs per episode per patient associated with the management of chronic comorbidities ranged from €1,323 (retinopathy, Italy [176]) to €9,497 (established CVD, UK [173]) in EST markets and from €769 (microvascular disease, China [177]) to €4,865 (chronic kidney disease (CKD), China [178]) in EMG markets (Figure 2).…”
Section: Epidemiology: Complicationsmentioning
confidence: 99%